Sugi Predict

Sugi Predict / Compounds / SCHEMBL3510472

SCHEMBL3510472

SCHEMBL3510472

CC#C[C@]1(n2ccc(N)nc2=O)C[C@H](O)[C@@H](CO)O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3A Q14432 3/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ SLC29A1 Q99808 1/20 0.43
▸ LMNA P02545 4/20 0.42
▸ THRB P10828 1/20 0.42
▸ MTOR P42345 1/20 0.42
▸ MDM2 Q00987 1/20 0.42
▸ NCOA1 Q15788 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ CACNA1F O60840 2/20 0.36
▸ ALB P02768 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ CACNA1D Q01668 2/20 0.36
▸ CACNA1S Q13698 2/20 0.36
▸ CACNA1C Q13936 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ POLB P06746 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ ADRB1 P08588 1/20 0.32
▸ DNMT1 P26358 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21100416 0.88 PDE3A (0.45) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL2057034 0.87 PDE3A (0.44) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL15719855 0.83 PDE3A (0.38) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL992472 0.81 PDE3A (0.46) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL2118776 0.80 PDE3A (0.46) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL3424602 0.80 PDE3A (0.47) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL28379714 0.80 PDE3A (0.47) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL1939478 0.80 PDE3A (0.47) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL1962181 0.79 PDE3A (0.45) PDE3APDE4DSLC29A1LMNATHRB
SCHEMBL7794942 0.79 PDE3A (0.46) PDE3APDE4DSLC29A1LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713485-A2 SEQUENCING ADAPTERS FOR METHYLATION SEQUENCING Foundation Medicine, Inc. (US) 2026-03-25 — — EP disclosed
WO-2024238523-A2 SEQUENCING ADAPTERS FOR METHYLATION SEQUENCING FOUNDATION MEDICINE, INC. (US) 2024-11-21 — — WO disclosed
CN-108713061-B Nucleic acid oligomer for RNA hybridization 学校法人东京理科大学 2022-04-05 — — CN disclosed
US-20100290992-A1 NANOPARTICLE NUCLEIC ACID BINDING COMPOUND CONJUGATES FORMING I-MOTIFS ROCHE DIAGNOSTICS GMBH (DE) 2010-11-18 — — US disclosed
EP-2054085-A2 NANOPARTICLE NUCLEIC ACID BONDING COMPOUND CONJUGATES FORMING I-MOTIFS Roche Diagnostics GmbH (DE) 2009-05-06 — — EP disclosed
US-7485421-B2 Polyamide-oligonucleotide derivatives, their preparation and use HOECHST GMBH (DE) 2009-02-03 — — US disclosed
US-7449450-B2 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products IMMUNOGEN INC. (US) 2008-11-11 — — US disclosed
WO-2008017507-A2 NANOPARTICLE NUCLEIC ACID BONDING COMPOUND CONJUGATES FORMING I-MOTIFS ROCHE DIAGNOSTICS GMBH (DE) 2008-02-14 — — WO disclosed
US-20050191696-A1 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products APOPTOSIS TECHNOLOGY, INC. 2005-09-01 — — US disclosed
US-6902885-B2 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products APOPTOSIS TECHNOLOGY, INC. (US) 2005-06-07 — — US disclosed
US-20050026817-A1 Polyamide-oligonucleotide derivatives, their preparation and use AVENTIS PHARMA DEUTSCHLAND GMBH (US) 2005-02-03 — — US disclosed
US-20030207262-A1 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products APOPTOSIS TECHNOLOGY, INC. 2003-11-06 — — US disclosed
US-20030198949-A1 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products APOPTOSIS TECHNOLOGY, INC. 2003-10-23 — — US disclosed
US-6605426-B1 Treating eukaryotic cells with expression vector encoding polypeptide residues of human cytomegalovirus APOPTOSIS TECHNOLOGY, INC. 2003-08-12 — — US disclosed
EP-1080233-A4 COMPOUNDS, SCREENING METHODS, AND USES INVOLVING ANTI-APOPTOTIC GENES AND GENE PRODUCTS APOPTOSIS TECHNOLOGY INC (US) 2003-02-05 — — EP disclosed
US-6218511-B1 Anti-apoptotic genes of human cytomegalovirus (HCMV) and their use APOPTOSIS TECHNOLOGY, INC. 2001-04-17 — — US disclosed
EP-1080233-A1 COMPOUNDS, SCREENING METHODS, AND USES INVOLVING ANTI-APOPTOTIC GENES AND GENE PRODUCTS Apoptosis Technology, Inc. (US) 2001-03-07 — — EP disclosed
WO-1999060171-A1 COMPOUNDS, SCREENING METHODS, AND USES INVOLVING ANTI-APOPTOTIC GENES AND GENE PRODUCTS APOPTOSIS TECHNOLOGY, INC. (US) 1999-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026817-A1 Polyamide-oligonucleotide derivatives, their preparation and use POLRMT, POLR2H, POLN PDE3A 4607/4885PDE4D 4651/4885SLC29A1 381/4885
US-20100290992-A1 NANOPARTICLE NUCLEIC ACID BINDING COMPOUND CONJUGATES FORMING I-MOTIFS POLM, IGF2BP1, POLRMT PDE3A 3974/4885PDE4D 2472/4885SLC29A1 1156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.